C2orf92: A Potential Drug Target and Biomarker (G728537)

Target Name: C2orf92

NCBI ID: G728537

Other Name(s): C2orf92 variant 2 | LINC01125 | Chromosome 2 open reading frame 92, transcript variant 2 | chromosome 2 open reading frame 92 | long intergenic non-protein coding RNA 1125

C2orf92: A Potential Drug Target and Biomarker

C2orf92, also known as C2ORF92, is a gene that encodes a protein known as C2ORF92A. This protein is a key regulator of the actinin-associated protein complex (APC), which is a protein that helps maintain the structure and stability of actinin, a protein found in the cytoskeleton, within cells. Discovered in 2007, C2orf92A has since been shown to play a crucial role in the regulation of a wide range of cellular processes, including cell adhesion, migration, and the development of cancer. As a result, C2orf92 has generated significant interest as a potential drug target and biomarker.

The APC is a protein complex that consists of several subunits that are involved in the regulation of actinin. C2ORF92A is one of the subunits of the APC that has been identified as a potential drug target. The APC plays a vital role in maintaining the structural integrity of actinin, which is essential for many cellular processes, including cell adhesion and migration. Mutations in the APC have been linked to a wide range of diseases, including cancer, neurodegenerative diseases, and developmental disorders.

C2ORF92A is a 21-kDa protein that is expressed in a variety of tissues, including muscle, nerve, and heart cells. It is highly conserved, with only a single amino acid difference between its human and mouse counterparts. This conservation suggests that C2ORF92A may be a promising drug target that can be targeted by small molecules.

Several studies have suggested that C2ORF92A may be a drug target by virtue of its role in the regulation of actinin. For example, studies have shown that inhibiting C2ORF92A can lead to a reduction in the levels of actinin in cells, which can lead to the collapse of actinin-associated structures and a decrease in cell adhesion. Additionally, C2ORF92A has been shown to play a role in the regulation of the cytoskeleton, which is involved in cell migration and the formation of tissues.

In addition to its potential as a drug target, C2ORF92A may also be a biomarker for certain diseases. For example, C2ORF92A has been shown to be downregulated in a variety of cancer types, including breast, ovarian, and colorectal cancers. This suggests that C2ORF92A may be a useful biomarker for the diagnosis and prognosis of these diseases. Additionally, C2ORF92A has been shown to be involved in the regulation of cell adhesion and migration, which may be useful as a biomarker for certain neurodegenerative diseases.

The identification of C2ORF92A as a potential drug target and biomarker has significant implications for the development of new treatments for a variety of diseases. While further research is needed to fully understand the role of C2ORF92A in cellular processes and its potential as a drug target and biomarker, its identification and characterization as a potential drug target and biomarker underscores the importance of investigating the role of the APC in cellular processes and the potential of small molecules as new therapeutic approaches.

In conclusion, C2orf92 is a gene that encodes a protein involved in the regulation of actinin, a protein that is essential for many cellular processes. The identification of C2ORF92A as a potential drug target and biomarker has significant implications for the development of new treatments for a variety of diseases. Further research is needed to fully understand the role of C2ORF92A in cellular processes and its potential as a drug target and biomarker.

Protein Name: Chromosome 2 Open Reading Frame 92

More Common Targets